What Not to Take With Ubrelvy: Drugs and Foods

Ubrelvy (ubrogepant) is broken down in your body primarily by a liver enzyme called CYP3A4, which means any drug or food that strongly blocks or revs up that enzyme can push ubrogepant levels too high or too low. The most important things to avoid are strong CYP3A4 inhibitors, which are outright contraindicated, and strong CYP3A4 inducers, which can make the medication ineffective. But the full picture includes moderate inhibitors that require a dose change, a handful of common foods, and some reassuring news about combinations that turn out to be perfectly safe.

Why CYP3A4 Matters So Much for Ubrelvy

Ubrogepant depends heavily on one metabolic pathway. It is processed by the CYP3A4 enzyme system and is also a substrate of P-glycoprotein, a transporter protein that helps shuttle drugs out of cells.¹ When another substance blocks CYP3A4, ubrogepant sticks around in the bloodstream much longer and at higher concentrations than intended. When something speeds CYP3A4 up, the enzyme chews through ubrogepant too fast, and the drug never reaches the level needed to actually treat a migraine. This single metabolic dependency is the source of nearly every meaningful drug interaction Ubrelvy has.

Strong CYP3A4 Inhibitors Are Off Limits

If you take a strong CYP3A4 inhibitor, you should not take Ubrelvy at all. These drugs dramatically slow down the enzyme responsible for clearing ubrogepant, which can more than double the drug’s concentration in your blood. The prescribing information lists this as an outright contraindication, not just a caution.

Common strong CYP3A4 inhibitors include:

Antifungals: ketoconazole, itraconazole, and posaconazole, which are used to treat serious fungal infections.
Antibiotics: clarithromycin and telithromycin, which belong to the macrolide class.
HIV protease inhibitors: ritonavir, nelfinavir, indinavir, and similar antiretroviral agents.
Hepatitis C drugs: boceprevir and certain combination products used in antiviral therapy.

If you are prescribed any of these medications on a regular basis, Ubrelvy is not an option for your acute migraine treatment. Your prescriber will need to choose a different acute therapy entirely. These interactions are not theoretical edge cases; clinical pharmacokinetic studies showed that co-administration with ketoconazole raised ubrogepant exposure to levels considered unsafe.¹

Moderate CYP3A4 Inhibitors Require a Dose Reduction

Moderate CYP3A4 inhibitors don’t raise ubrogepant levels quite as dramatically, but the increase is still significant enough to require a lower dose. If you take one of these medications, Ubrelvy’s labeling calls for limiting each dose to 50 mg, and you should not take a second dose within 24 hours.

The drugs in this category are ones that a lot of people take regularly:

Verapamil and diltiazem: calcium channel blockers often prescribed for high blood pressure, heart rhythm issues, or even migraine prevention, which creates an ironic overlap for migraine patients.
Fluconazole: a widely used oral antifungal, commonly prescribed for yeast infections.
Erythromycin: a macrolide antibiotic still used for respiratory and skin infections.
Ciprofloxacin: a fluoroquinolone antibiotic used for urinary tract infections and other bacterial infections.

The verapamil situation deserves extra attention because it is sometimes prescribed as a migraine preventive. If you’re already on verapamil and your doctor adds Ubrelvy for acute attacks, you can still use Ubrelvy, but only at the reduced dose. This is a conversation worth having explicitly with your prescriber, because both drugs target migraine and the interaction may not be immediately obvious.

Grapefruit and Other Food Interactions

Grapefruit juice is a moderate CYP3A4 inhibitor, and this applies to Ubrelvy just as it does to many other medications metabolized through the same pathway. Drinking grapefruit juice while taking ubrogepant can raise the drug’s concentration in your blood, mimicking the effect of a moderate drug inhibitor. If you’re a regular grapefruit consumer, the same dose-limiting rules that apply to moderate CYP3A4 inhibitor drugs apply to you: keep your Ubrelvy dose at 50 mg and skip the second dose within 24 hours.

Seville oranges (the bitter oranges used in marmalade) and pomelos contain similar compounds that inhibit CYP3A4, though the effect is typically less potent than grapefruit. The practical advice is straightforward: if you have a migraine coming on and you’ve recently had grapefruit or grapefruit juice, treat your dose as if you were on a moderate inhibitor. On days when you haven’t consumed any of these fruits, you can take Ubrelvy at its standard dose.

Beyond grapefruit, there is no broad food restriction with Ubrelvy. You can take it with or without meals. High-fat meals may slightly delay how quickly the drug kicks in, but they don’t change the overall amount that gets absorbed, so most people don’t need to worry about meal timing.

Strong CYP3A4 Inducers Can Make Ubrelvy Useless

The opposite problem from inhibitors: strong CYP3A4 inducers crank up the enzyme so much that ubrogepant gets cleared from your system before it can do its job. The labeling advises avoiding co-administration with strong inducers because the drug may simply not work.

The most common strong CYP3A4 inducers include:

Rifampin: a powerful antibiotic used primarily for tuberculosis.
Phenytoin and carbamazepine: anti-seizure medications sometimes also used for nerve pain.
Phenobarbital: a barbiturate used for seizures.
St. John’s wort: an herbal supplement widely taken for depression and anxiety, and the one on this list most likely to be missed by prescribers because patients often don’t mention supplements during medication reviews.

St. John’s wort is worth emphasizing because it is available over the counter and many people don’t think of it as a “real” drug interaction risk. But its effect on CYP3A4 is strong enough to substantially reduce the blood levels of many medications, ubrogepant included. If you use St. John’s wort and get migraines, mention it to your prescriber before starting Ubrelvy.

P-glycoprotein Inhibitors Add Another Layer

Because ubrogepant is also a P-glycoprotein substrate, drugs that inhibit this transporter can increase ubrogepant exposure independently of CYP3A4 effects. In practice, many strong P-glycoprotein inhibitors are also CYP3A4 inhibitors (cyclosporine, for example, hits both), so the interaction is often covered by the CYP3A4 warnings already discussed. However, a few P-glycoprotein inhibitors don’t strongly affect CYP3A4, and these still warrant caution. The prescribing information recommends treating co-administration with P-glycoprotein inhibitors like BCRP inhibitors with the same dose-limiting rules as moderate CYP3A4 inhibitors.

Cyclosporine and quinidine are two P-glycoprotein inhibitors that come up in this context. If you’re on either of these, your Ubrelvy dose should be limited to 50 mg with no second dose that day.

What You Can Safely Combine With Ubrelvy

The interaction landscape sounds restrictive, but the list of safe combinations is actually much larger than the list of problematic ones. A few that migraine patients commonly wonder about:

CGRP Monoclonal Antibodies

Many migraine patients use a preventive CGRP monoclonal antibody injection (erenumab, galcanezumab, fremanezumab, or eptinezumab) alongside Ubrelvy for breakthrough attacks. A phase 1b drug interaction study found no significant change in ubrogepant blood levels when it was given alongside erenumab or galcanezumab, and the combination produced no new safety concerns beyond what each drug causes on its own.² This makes biological sense: the antibodies are large molecules cleared by different pathways than the small-molecule gepant, so they don’t compete for the same metabolic machinery.

Atogepant for Prevention

Atogepant (Qulipta) is a gepant used for migraine prevention, and some patients end up on daily atogepant while using Ubrelvy for acute episodes. A phase 1b interaction study found that co-administration raised ubrogepant blood levels modestly, about 19% for overall exposure and 26% for peak concentration, but these increases were not considered clinically meaningful and no new safety concerns emerged.³ So using both gepants together appears to be safe, though it’s still a relatively new combination and your prescriber may want to monitor how you respond.

Triptans and NSAIDs

Ubrelvy works through an entirely different mechanism than triptans (sumatriptan, rizatriptan, and others) and nonsteroidal anti-inflammatory drugs like ibuprofen or naproxen. There is no pharmacokinetic interaction between Ubrelvy and these drugs. Some patients alternate between a triptan and Ubrelvy depending on the migraine, while others use an NSAID alongside Ubrelvy for a given attack. Neither combination creates a CYP3A4 or P-glycoprotein issue.

Liver and Kidney Problems Change the Equation

Your organ function affects how much ubrogepant your body is exposed to, even without any interacting drugs. Mild to moderate kidney impairment doesn’t meaningfully change ubrogepant levels, so no dose adjustment is needed in that range.⁴ Severe kidney impairment and end-stage renal disease are less well studied, and Ubrelvy should be used cautiously in those situations.

Liver impairment is a bigger concern. Ubrogepant exposure increases progressively with the severity of liver disease: roughly 7% higher with mild impairment, about 50% higher with moderate impairment, and more than double with severe impairment.⁴ Severe liver impairment calls for a dose reduction to avoid excessive drug exposure. This matters because some of the same patients who take medications that interact with CYP3A4 may also have compromised liver function, compounding the interaction risk. If you have liver disease of any severity, make sure your prescriber factors that in alongside any interacting medications.

Ubrelvy and Breastfeeding

Migraine is common during the postpartum period, and many people want to know whether Ubrelvy can be taken while nursing. A pharmacokinetic study in healthy lactating women found very low transfer of ubrogepant into breast milk. The milk-to-plasma ratio averaged 0.23, meaning breast milk contained roughly a quarter of the concentration found in the mother’s blood. The total amount of drug excreted into breast milk was less than 0.02% of the dose, and the calculated relative infant dose was 0.15%.⁵

A relative infant dose below 10% is generally considered compatible with breastfeeding, and 0.15% is far below that threshold. The peak breast milk concentration and overall exposure were about 75% to 78% lower than in the mother’s plasma.⁵ These numbers suggest minimal infant exposure. The prescribing information still advises caution, as is standard for newer drugs, but the pharmacokinetic data is reassuring compared to many other migraine medications that lack any breastfeeding data at all.

Common Mistakes People Make With Ubrelvy Interactions

In practice, a few patterns trip people up more than others. The first is forgetting about supplements. St. John’s wort, as mentioned earlier, is the main culprit, but high-dose turmeric or curcumin supplements are sometimes discussed as potential mild CYP3A4 modulators. The evidence for turmeric affecting CYP3A4 at supplemental doses in humans is thin, but the broader point holds: always list your supplements when a prescriber is reviewing drug interactions.

The second is assuming that “natural” means “no interaction.” Grapefruit is natural. St. John’s wort is natural. Both meaningfully alter CYP3A4 activity. The enzyme doesn’t distinguish between a pharmaceutical and a plant compound.

The third is confusing the direction of the interaction. With strong inhibitors, the problem is too much Ubrelvy in your system. With strong inducers, the problem is too little. The clinical consequences are different: excess exposure increases the risk of side effects like nausea, drowsiness, and dry mouth, while inadequate exposure means you’re essentially taking a placebo for your migraine. Neither is what you want, but the distinction matters when talking to your prescriber about alternatives.

Finally, some people worry about combining Ubrelvy with over-the-counter pain relievers like acetaminophen, ibuprofen, or naproxen. None of these interact with CYP3A4 in a clinically meaningful way, and there is no pharmacokinetic reason to avoid combining them with Ubrelvy. The main consideration with any acute migraine medication used alongside OTC painkillers is the risk of medication overuse headache from frequent use of any acute treatment, which is a separate issue from drug-drug interactions.

How to Check for Interactions Yourself

Drug interactions with Ubrelvy all come back to one question: does the other substance meaningfully inhibit or induce CYP3A4, or inhibit P-glycoprotein? If you’re prescribed a new medication and want to quickly gauge the risk, the most practical approach is to look up whether the new drug is classified as a strong, moderate, or weak CYP3A4 inhibitor or inducer. The FDA maintains tables of known CYP3A4 inhibitors and inducers, and most pharmacy drug-interaction checkers flag these automatically.

Weak CYP3A4 inhibitors generally don’t require a dose change for Ubrelvy. The interaction exists on paper but is small enough that the prescribing information doesn’t restrict it. Moderate inhibitors require the dose cap at 50 mg with no second dose. Strong inhibitors are a hard stop. And strong inducers mean Ubrelvy probably won’t work for you. If you can remember that four-tier framework, you can have a much more productive conversation with your pharmacist or prescriber about any new medication that gets added to your regimen.